Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Titel:
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Auteur:
Hamberg, Paul Bos, Monique M.E.M. Braun, Hans J.J. Stouthard, Jacqueline M.L. van Deijk, Gert A. Erdkamp, Frans L.G. van der Stelt-Frissen, Iris N. Bontenbal, Marijke Creemers, Geert-Jan M. Portielje, Johanneke E.A. Pruijt, Johannes F.M. Loosveld, Olaf J.L. Smit, Willem M. Muller, Erik W. Schmitz, Paul I.M. Seynaeve, Caroline Klijn, Jan G.M.